Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects

References

• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011 Apr;91(2):733–794. doi: 10.1152/physrev.00055.2009
   PubMed Web of Science ®Google Scholar
• Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020 Dec;17(12):761–772. doi: 10.1038/s41569-020-0406-8
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022 Jan;22(1):39–52. doi: 10.1007/s11892-021-01442-z
   PubMed Web of Science ®Google Scholar
• Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diab Obes Metab. 2021 Sep;23(9):2116–2124. doi: 10.1111/dom.14451
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu M, Li S, et al. Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis. Front Endocrinol. 2021;12:706914. doi: 10.3389/fendo.2021.706914
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125–S143. doi: 10.2337/dc22-S009
   PubMedGoogle Scholar
• Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021 May 11;373(1091). doi: 10.1136/bmj.n1091
   Google Scholar
• Choi MK, Nam SJ, Ji HY, et al. Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin. Pharmaceutics. 2020 Mar 15;12(3):268. doi: 10.3390/pharmaceutics12030268
   PubMed Web of Science ®Google Scholar
• Hwang JG, Lee S, Huh W, et al. Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2022 Sep;88(9):4100–4110. doi: 10.1111/bcp.15348
   PubMed Web of Science ®Google Scholar
• Kwak SH, Han KA, Kim KS, et al. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial. Diab Obes Metab. 2023 Mar 5;25(7):1865–1873. doi: 10.1111/dom.15046
   PubMed Web of Science ®Google Scholar
• Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018 Apr 1;39(2):79–132. doi: 10.1210/er.2017-00253
   PubMed Web of Science ®Google Scholar
• Dong Z, Xu L, Liu H, et al. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev. 2017 Dec;18(12):1377–1385. doi: 10.1111/obr.12606
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb;95(2):297–308. doi: 10.3945/ajcn.111.024927
   PubMed Web of Science ®Google Scholar
• World Health Organization Obesity and overweight. 9 Jun 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed 3 Mar 2023].
   Google Scholar
• American Diabetes Association Professional Practice C. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S113–S124. doi: 10.2337/dc22-S008
   PubMedGoogle Scholar
• Simonds SE, Pryor JT, Koegler FH, et al. Determining the effects of combined liraglutide and phentermine on metabolic parameters, blood pressure, and heart rate in lean and obese male mice. Diabetes. 2019 Apr;68(4):683–695. doi: 10.2337/db18-1149
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec;37(12):3309–3316. doi: 10.2337/dc14-0930
   PubMed Web of Science ®Google Scholar
• Tronieri JS, Wadden TA, Walsh OA, et al. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial. Metabolism. 2019 Jul;96:83–91.
   PubMed Web of Science ®Google Scholar
• Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese Individuals without diabetes: a randomized Clinical trial. Diabetes Care. 2017 May;40(5):632–639. doi: 10.2337/dc16-2427
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim DK, Choi WG, et al. In vitro metabolism of DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, in human and animal hepatocytes. Pharmaceutics. 2020 Sep 11;12(9):865. doi: 10.3390/pharmaceutics12090865
   PubMed Web of Science ®Google Scholar
• Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep;12(5):741–756. doi: 10.1517/14740338.2013.806481
   PubMed Web of Science ®Google Scholar
• Johnson DB, Quick J. Topiramate and phentermine. Treasure Island (FL): StatPearls; 2022.
   Google Scholar
• Kadokura T, Zhang W, Krauwinkel W, et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014 Nov;53(11):975–988. doi: 10.1007/s40262-014-0180-z
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17–27. doi: 10.1007/s40262-013-0104-3
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013 Oct;36(10):3169–3176. doi: 10.2337/dc13-0387
   PubMed Web of Science ®Google Scholar
• Kim KK, Cho HJ, Kang HC, et al. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J. 2006 Oct 31;47(5):614–625. doi: 10.3349/ymj.2006.47.5.614
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019 Feb;79(3):219–230. doi: 10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar
• McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45–S52. doi: 10.1016/j.amjcard.2019.10.029
   PubMed Web of Science ®Google Scholar